Therma Bright Secures Major Purchase Order for Venowave VW5 Units

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a leading developer and investment partner in advanced diagnostic and medical device technologies, has secured a significant purchase order for 1,750 Venowave VW5 units from national distributor DME Authority of Nashville, TN. This strategic partnership reflects the growing enthusiasm around the Venowave VW5 in the U.S. market and Therma Bright's commitment to supporting DME Authority's partners in expanding distribution and enhancing patient care.



The purchase order, valued at a minimum of $1,434,212 USD ($2,051,602 CAD), brings both Therma Bright and DME Authority one step closer to the outlined Letter of Intent (LOI) that positions DME as a 'Premier Distributor Partner' for Therma Bright. This initial purchase order for 1,750 Venowave VW5 units offers HCPCS code reimbursements, indicating a strong market demand for the device and Therma Bright's innovative technology.

The partnership with DME Authority contributes significantly to Therma Bright's market expansion plans by providing access to a national distribution network, which is crucial for increasing sales and market penetration. DME Authority's collaboration with multiple tenured and qualified network partners enables Therma Bright to establish no less than three comprehensive U.S. distribution agreements. This access to a national distribution network allows Therma Bright to expand its reach and increase sales of its Venowave VW5 devices.

In the short term, this purchase order is expected to have a positive impact on Therma Bright's financial performance. The order is valued at a minimum of $1,434,212 USD ($2,051,602 CAD), which will contribute to the company's revenue. Additionally, the successful pilot tests around the HCPCS code reimbursement program indicate that there is a strong market demand for the Venowave VW5 units, which could lead to further sales and revenue growth in the near future.

In the long term, this purchase order is expected to have a significant impact on Therma Bright's financial performance. The company anticipates increasing its purchase order amounts every few weeks as DME Solutions and its partners continue to receive doctor referrals for vascular compression therapy solutions. This could lead to a steady increase in sales and revenue for Therma Bright, as well as an expansion of its market reach in the U.S. healthcare sector. Furthermore, the success of this partnership could pave the way for similar partnerships with other national distribution partners, further driving the company's growth and financial performance.

The key factors driving the demand for Venowave VW5 units are:

1. Increased awareness and acceptance of mobile mechanical compression systems: The Venowave VW5 is the only Medicare-approved reimbursable mobile mechanical compression system available in the US under its HCPCS code E0683. This unique positioning has created interest among healthcare providers and patients alike.
2. Positive clinical outcomes and timely reimbursements: The device has demonstrated positive clinical outcomes, as evidenced by the extensive reimbursement testing across multiple medical specialties and procedures. This has led to high patient satisfaction and a growing demand for the device.
3. Pent-up demand for effective treatment options: Until now, providers lacked a mobile mechanical compression solution for the U.S. Medicare population, leaving a significant void for an effective treatment option. The Venowave VW5 fills this gap, addressing the pent-up demand.

In conclusion, Therma Bright's strategic partnership with DME Authority and the subsequent purchase order for 1,750 Venowave VW5 units reflect the growing market demand for the company's innovative technology and its commitment to expanding its market reach in the U.S. healthcare sector. This partnership is expected to have a positive impact on Therma Bright's financial performance in the short and long term, driving the company's growth and market penetration.